Cybin Inc. (AMEX:CYBN) shares traded 0.65% higher at $0.31 on Wall Street last session.
In accordance with the data, 6 analysts cover Cybin Inc. (AMEX:CYBN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $1.12, we find $4.06. Given the previous closing price of $0.31, this indicates a potential upside of 1209.68 percent. CYBN stock price is now -24.73% away from the 50-day moving average and -49.66% away from the 200-day moving average. The market capitalization of the company currently stands at $81.12M.
It has been rated a hold by 0 analysts and a buy by 6. Brokers who have rated the stock have averaged $4.74 as their price target over the next twelve months.
Insiders disposed of 20,000 shares of company stock worth roughly $6200.0 over the past 1 year. A total of 20.22% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CYBN stock. A new stake in Cybin Inc. shares was purchased by CANTOR FITZGERALD, L. P. during the first quarter worth $93,000. CERITY PARTNERS LLC invested $18,000 in shares of CYBN during the first quarter. In the first quarter, MILLENNIUM MANAGEMENT LLC acquired a new stake in Cybin Inc. valued at approximately $18,000. VIRTU FINANCIAL LLC acquired a new stake in CYBN for approximately $14,000. NADLER FINANCIAL GROUP, INC. purchased a new stake in CYBN valued at around $14,000 in the second quarter. In total, there are 65 active investors with 10.23% ownership of the company’s stock.
Cybin Inc. (AMEX: CYBN) opened at $0.2910 on Tuesday. During the past 12 months, Cybin Inc. has had a low of $0.26 and a high of $1.29. The fifty day moving average price for CYBN is $0.4118 and a two-hundred day moving average price translates $0.6158 for the stock.
The latest earnings results from Cybin Inc. (AMEX: CYBN) was released for Jun, 2022.
Cybin Inc.(CYBN) Company Profile
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.